MONISHA KAMDAR: Open Payments
NPI 1467153023 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$918 in 29 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $578 · 2025 $918
Food & beverage: $818Education: $100
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 2 | $225 |
| Daiichi Sankyo Inc. | 8 | $182 |
| Novartis Pharmaceuticals Corporation | 5 | $151 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $116 |
| Astellas Pharma US Inc | 1 | $32 |
| GENZYME CORPORATION | 1 | $30 |
| Legend Biotech USA Inc. | 1 | $30 |
| JAZZ PHARMACEUTICALS INC. | 1 | $27 |
| Janssen Biotech, Inc. | 1 | $27 |
| GlaxoSmithKline, LLC. | 1 | $23 |
Products named: Vanflyta, Niktimvo, SCEMBLIX, ICLUSIG, CARVYKTI, Vyloy, AYVAKIT, Fabhalta.
Industry payments across CA — which companies pay providers there.
